T1	Participants 113 137	acute myeloid leukaemia.
T2	Participants 569 696	in adult patients with previously untreated AML receiving induction therapy with idarubicin, high-dose cytarabine and etoposide
T3	Participants 698 727	Among 155 randomized patients
